IX Biopharma (SGX:42C) reported that its iXB 401 semaglutide sublingual wafer demonstrated 20 times greater bioavailability than Rybelsus, an oral semaglutide tablet, in a preclinical study, according to a Tuesday filing on the Singapore Exchange.
The wafer uses iX Biopharma's sublingual drug delivery technology, offering a potentially more consistent and noninvasive alternative to oral semaglutide with lower variability, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.